Kościuszko Maria, Buczyńska Angelika, Hryniewicka Justyna, Jankowska Dorota, Adamska Agnieszka, Siewko Katarzyna, Jacewicz-Święcka Małgorzata, Zaniuk Marcin, Krętowski Adam Jacek, Popławska-Kita Anna
Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-274 Bialystok, Poland.
Clinical Research Center, Medical University of Bialystok, 15-274 Bialystok, Poland.
Int J Mol Sci. 2025 Jun 6;26(12):5434. doi: 10.3390/ijms26125434.
It is hypothesized that growth hormone deficiency (GHD) is associated with increased oxidative stress (OS), contributing to elevated cardiovascular risk. This preliminary study evaluates changes in OS markers and cardiovascular biomarkers in 15 adult patients with severe GHD undergoing 12 months of recombinant human growth hormone (rhGH) therapy. IGF-1 concentrations increased significantly following 6 and 12 months of therapy ( = 0.0003 and = 0.0001, respectively). These changes were accompanied by a significant decrease in endothelin-1 (ET-1) levels at 12 months ( = 0.007), as well as reductions in asymmetric dimethylarginine (ADMA) levels at both 6 and 12 months ( = 0.01 for each timepoint). Total oxidative capacity (TOC) decreased significantly after 6 months of therapy ( = 0.02), followed by a significant increase at 12 months ( = 0.04), whereas total antioxidant capacity (TAC) showed a significant increase at 12 months ( = 0.02). Tissue fat % showed significant reductions at 6 months ( = 0.006), suggesting early improvements in body composition. Correlation analyses indicated negative associations between IGF-1 and TOC ( < 0.006; R = -0.73), and positive associations with TAC ( < 0.001; R = 0.83). These findings suggest that rhGH therapy in adult patients with severe GHD reduces OS and cardiovascular risk through the modulation of biomarkers and improved body composition. This study explores the role of rhGH therapy in reducing cardiovascular risks in GHD, emphasizing the importance of individualized treatment approaches.
据推测，生长激素缺乏症（GHD）与氧化应激（OS）增加有关，这会导致心血管风险升高。这项初步研究评估了15名重度GHD成年患者在接受12个月重组人生长激素（rhGH）治疗期间OS标志物和心血管生物标志物的变化。治疗6个月和12个月后，胰岛素样生长因子-1（IGF-1）浓度显著升高（分别为P = 0.0003和P = 0.0001）。这些变化伴随着12个月时内皮素-1（ET-1）水平的显著降低（P = 0.007），以及6个月和12个月时不对称二甲基精氨酸（ADMA）水平的降低（每个时间点P = 0.01）。治疗6个月后总氧化能力（TOC）显著降低（P = 0.02），随后在12个月时显著升高（P = 0.04），而总抗氧化能力（TAC）在12个月时显著升高（P = 0.02）。6个月时体脂百分比显著降低（P = 0.006），表明身体成分早期得到改善。相关性分析表明IGF-1与TOC之间呈负相关（P < 0.006；R = -0.73），与TAC呈正相关（P < 0.001；R = 0.83）。这些发现表明，重度GHD成年患者接受rhGH治疗可通过调节生物标志物和改善身体成分来降低OS和心血管风险。本研究探讨了rhGH治疗在降低GHD患者心血管风险中的作用，并强调了个体化治疗方法的重要性。
